Entecavir (BMS200475): Benchmarks in Chronic Hepatitis B Therapy

Executive Summary: Entecavir (CAS No. 142217-69-4) is a highly potent, selective inhibitor of hepatitis B virus (HBV) DNA polymerase, specifically the reverse transcriptase essential for viral replication. It is effective against both wild-type and lamivudine-resistant HBV, including strains with M204V and L180M mutations. In vitro, it achieves an EC50 of 3.75 nM in HepG2.2.15 cells, and clinical studies report a low resistance rate (0.9% over five years) with sustained viral suppression. Oral doses of 0.5–1 mg/day are standard in chronic hepatitis B patients, including those with decompensated liver disease. APExBIO supplies Entecavir (BA1816), a research-grade compound with validated purity and performance (product info).

Biological Rationale

Chronic hepatitis B infection remains a major global health burden, with persistent viral replication leading to liver cirrhosis, hepatocellular carcinoma, and liver failure. Suppressing HBV replication is critical to preventing disease progression, especially in patients with active viral replication, elevated alanine aminotransferase (ALT), or histologically active liver disease. The need for agents that are effective against drug-resistant HBV and safe in decompensated liver disease underpins the rationale for Entecavir’s development (Zoulim 2006).

Mechanism of Action of Entecavir

Entecavir (BMS200475) is a deoxyguanosine nucleoside analog. It inhibits the HBV DNA polymerase by competing with natural substrates, selectively blocking the priming of reverse transcriptase and synthesis of both negative- and positive-strand viral DNA (Molecular Pharmacology). This dual mechanism results in potent and selective inhibition of HBV replication, while sparing host polymerases. The molecular weight is 277.28 g/mol, formula C₁₂H₁₅N₅O₃, and it is highly soluble in DMSO (≥37.3 mg/mL), but insoluble in water and ethanol (product information).

Evidence & Benchmarks

• Entecavir exhibits an in vitro EC50 of 3.75 nM against HBV in HepG2.2.15 cells, indicating high potency (product info).
• It retains activity against lamivudine-resistant HBV strains (M204V/L180M), with only a modest increase in EC50 (Clinical Insights).
• Animal studies (rat, dog, woodchuck) show significant reduction in serum HBV DNA and intrahepatic covalently closed circular DNA (cccDNA) after oral administration (Zoulim 2006).
• Clinically, 0.5 mg/day is effective for nucleos(t)ide-naïve adults, while 1 mg/day is used for lamivudine-resistant or decompensated liver disease patients, yielding steady-state Cmax ≈ 8.24 ng/mL (product info).
• Long-term suppression of HBV DNA is achieved, with only 0.9% resistance rate after 5 years of therapy (Keating 2011).
• Entecavir is well-tolerated, with rare but notable adverse events such as thrombocytopenia and lactic acidosis, especially in high-risk populations (Keating 2011).

For a translational perspective on assay optimization, see this article, which details workflow adaptations for HBV replication studies; the present dossier updates those findings with clinical resistance data and in vivo pharmacokinetics.

Applications, Limits & Misconceptions

Entecavir is indicated for chronic hepatitis B infection, including in patients with active viral replication, elevated ALT, and decompensated cirrhosis. It is a preferred agent for chronic hepatitis B infection therapy due to its high barrier to resistance and efficacy against lamivudine-resistant strains. However, its use in acute hepatitis B, co-infected HIV/HBV patients not on antiretroviral therapy, or as monotherapy in severe immunosuppression is not supported by clinical evidence (Keating 2011).

Common Pitfalls or Misconceptions

• Entecavir is not effective for hepatitis B virus strains with pre-existing multi-drug resistance beyond lamivudine-associated mutations.
• It is not recommended as monotherapy in HIV/HBV co-infected patients due to risk of HIV resistance (Keating 2011).
• Prolonged storage of Entecavir solutions is discouraged; solutions should be used promptly and not stored long-term (product info).
• Entecavir does not reverse cirrhosis; it suppresses viral replication but does not restore normal liver architecture.
• Use in pregnancy or pediatric populations requires specialized protocols not covered by standard adult dosing guides.

While this review emphasizes translational aspects of HBV DNA polymerase inhibition, the current article focuses on clinical resistance rates and long-term safety in decompensated disease.

Workflow Integration & Parameters

• Compound preparation: Dissolve Entecavir in DMSO to ≥37.3 mg/mL; ensure complete dissolution before dilution (product info).
• Storage: Store solid compound at -20°C; avoid repeated freeze-thaw cycles.
• In vitro HBV studies: Use EC50 reference of 3.75 nM in HepG2.2.15 cells for assay benchmarking.
• In vivo dosing (rodent): Oral administration protocols should mimic clinical exposures; adjust for species-specific pharmacokinetics.
• Clinical translation: Standard dose 0.5 mg/day for naïve adults; 1 mg/day for lamivudine-resistant or decompensated patients.
• Solution handling: Prepare fresh solutions for each experiment, as stability data do not support long-term storage.

For detailed protocol comparisons and troubleshooting, see this workflow article; the present guide aligns with APExBIO’s validated handling recommendations.

Conclusion & Outlook

Entecavir (BMS200475) stands as a cornerstone in chronic hepatitis B infection therapy, offering robust, sustained suppression of HBV DNA in both wild-type and lamivudine-resistant cases. Its high genetic barrier to resistance and favorable safety profile support its use in patients with decompensated liver disease (Keating 2011). As benchmarked in this dossier, APExBIO’s Entecavir (BA1816) supports advanced HBV research and translational workflows. Ongoing surveillance of resistance and safety in special populations remains essential. For a deep dive into molecular pharmacology, this article provides additional mechanistic insights; our focus here emphasizes clinical durability and workflow integration.